Core Points - The company plans to distribute a cash dividend of 1 yuan per share to all shareholders, approved at the 2024 annual general meeting on May 16, 2025 [1][2] - The total number of shares eligible for the dividend is 111,874,753 shares after excluding shares in the company's repurchase account, resulting in a total cash dividend distribution of 111,874,753 yuan, which accounts for 79.62% of the company's net profit attributable to shareholders for the year [2][3] - The company will not issue bonus shares or increase capital reserves this year [2] Dividend Distribution Details - The cash dividend distribution will be based on the total number of shares registered by the close of trading on the equity registration date [1][3] - The reference price for ex-dividend trading will be calculated using the formula: (previous closing price - cash dividend) / (1 + change in circulating shares ratio), with the circulating shares ratio being 0 due to no changes in circulating shares [3] - The virtual cash dividend per share is approximately 0.9978 yuan, calculated based on the total shares participating in the distribution [3] Tax Implications - For individual shareholders holding shares for over one year, the cash dividend is exempt from personal income tax, resulting in a net distribution of 1 yuan per share [6][7] - For shares held for less than one year, the company will not withhold personal income tax at the time of distribution, but tax will be calculated and withheld upon the sale of shares [6][8] - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, resulting in a net cash dividend of 0.9 yuan per share [7][8]

上海市通力律师事务所 关于无锡祥生医疗科技股份有限公司 差异化分红事项之专项法律意见书 致: 无锡祥生医疗科技股份有限公司 上海市通力律师事务所(以下简称"本所")接受无锡祥生医疗科技股份有限公司(以下 简称"祥生医疗"或"公司")的委托, 指派本所孙文律师、李昱程律师(以下合称"本所律 师")根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共和国证券 法》(以下简称"《证券法》")、《上海证券交易所上市公司自律监管指引第 7 号——回购 股份》(以下简称"《自律监管指引》")、《上海证券交易所上市公司自律监管指南第 2 号 ——业务办理》等法律、法规及规范性文件(以下简称"法律、法规及规范性文件", 该等 法律、法规及规范性文件不包括香港特别行政区、澳门特别行政区和台湾地区的法律法规) 以及《无锡祥生医疗科技股份有限公司章程》(以下简称"《公司章程》")的规定, 就祥生 医疗 2024 年度利润分配所涉及的差异化分红事项(以下简称"本次差异化分红")相关事项 出具法律意见。 为出具本法律意见书, 本所律师已经严格履行法定职责, 遵循了勤勉尽责和诚实信用 原则, 对祥生医疗本次差异化分红所涉 ...

证券代码：688358 证券简称：祥生医疗 公告编号：2025-017 无锡祥生医疗科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/7/14 | 2025/7/15 | 2025/7/15 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 16 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东（无 锡祥生医疗科技股份有限公司回购专用证券账户除外）。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 上市公司自律监管指引第 7 号——回购股份》等相关法律、行政法规、部门规章 是否涉及差异化分红送转：是 ...

Company Overview - Xiangsheng Medical closed at 28.1 yuan, down 2.09%, with a rolling PE ratio of 23.07 times and a total market value of 3.151 billion yuan [1] - The company specializes in the research, manufacturing, and sales of ultrasound medical imaging equipment [1] - Xiangsheng Medical was selected as a "Little Giant" enterprise for the 2024 National Specialized and Innovative Enterprises [1] Financial Performance - For Q1 2025, the company reported operating revenue of 128 million yuan, a year-on-year decrease of 9.16%, and a net profit of 41.6145 million yuan, down 8.62% year-on-year, with a gross profit margin of 61.33% [1] Shareholder Information - As of March 31, 2025, the number of shareholders for Xiangsheng Medical was 6,509, an increase of 1,499 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 49.10 times, with a median of 36.43 times, placing Xiangsheng Medical at the 52nd position in the industry ranking [1][2] - The industry average market value is 10.51 billion yuan, while the median is 4.892 billion yuan [2]

6月9日，祥生医疗今日收盘30.45元，上涨2.66%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到25.00倍，创43天以来新低，总市值34.14亿元。 无锡祥生医疗科技股份有限公司的主营业务是超声医学影像设备的研发、制造和销售。公司的主要产品 是超声医学影像设备。公司入选2024年度国家专精特新"小巨人"企业。 最新一期业绩显示，2025年一季报，公司实现营业收入1.28亿元，同比-9.16%；净利润4161.45万元，同 比-8.62%，销售毛利率61.33%。 来源：金融界 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均50.64倍，行业中值37.05倍，祥生医疗排 名第54位。 截至2025年一季报，共有15家机构持仓祥生医疗，其中基金10家、其他5家，合计持股数5830.14万股， 持股市值18.03亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)54祥生医疗25.0024.302.3334.14亿行业平均 50.6449.074.68109.10亿行业中值37.0537.632.5050.67亿1天益医疗-1817.92-3113.901.9423.17亿2 ...

Core Viewpoint - The company, Xiangsheng Medical, is increasing its R&D investment and has introduced innovative products in the field of ultrasound technology, particularly focusing on breast cancer screening and maternal health solutions. Group 1: Financial Performance - As of May 23, 2025, Xiangsheng Medical's stock closed at 28.63 yuan, up 0.74% from the previous week [1] - The company's total market capitalization is 3.21 billion yuan, ranking 93rd out of 126 in the medical device sector and 3960th out of 5148 in the A-share market [1] Group 2: R&D Investment - In 2024, the company plans to increase its R&D expenditure to nearly 80 million yuan, which represents 16.99% of its operating revenue [2][3] - The company will authorize 48 new patents in 2024, including 30 new invention patents, and will file 66 new intellectual property applications, with 15 being invention patent applications [2][3] Group 3: Product Development - The company has launched a "Breast Artificial Intelligence Ultrasound Robot" aimed at addressing the challenges of mass screening for breast cancer in China, integrating ultrasound, robotics, and AI technology [2][3] - In the field of obstetrics, the company has developed an intelligent solution that automatically tracks fetal position, recognizes growth indicators, and generates fetal examination reports [2][3]

Industry Overview and Core Value - AI in healthcare utilizes machine learning and computer vision to analyze medical data, aiming to enhance efficiency, reduce costs, and optimize patient experience [1][14] - The Chinese government has introduced policies to promote AI integration in healthcare, identifying 84 application scenarios [1][22] Development History and Market Size - The development of AI in healthcare in China can be divided into three phases: the nascent phase (1978-2015), the starting phase (2015-2021), and the exploratory phase (2021-present) [2][25] - The market size for AI healthcare in China is projected to reach 115.7 billion yuan by 2025 and 159.8 billion yuan by 2028, with a CAGR of 10.5% [2][39] Industry Chain and Segmentation - The AI healthcare industry chain includes upstream (data, algorithms, computing power), midstream (computer vision, NLP), and downstream (imaging, pharmaceuticals, health management) [3][43] - Key segments include: - AI Medical Imaging: Expected market size of approximately 7.45 billion yuan in 2024, growing to 23.57 billion yuan by 2026 [3] - AI Pharmaceuticals: Global market size projected at 2.994 billion USD in 2024 [3] - AI Health Management: Market size nearing 1.4 trillion yuan in 2024 [3] Challenges and Future Trends - Current challenges include insufficient data standardization, privacy protection, and high implementation costs [4] - Future trends involve: - Deepening technology integration, such as combining large models with multimodal technologies [4] - Promoting domestic production and self-control in hardware and algorithms [4] - Expanding application scenarios from hospitals to grassroots healthcare [4] - Policy-driven commercialization in areas like telemedicine and imaging recognition [4] Representative Company Layout - Key companies in the AI healthcare sector include: - Xiangsheng Medical: Portable ultrasound devices recognized internationally [5] - RunDa Medical: Integration of in vitro diagnostics with AI [5] - United Imaging: High-end imaging equipment with over 20% market share [5] - iFlytek Medical: Comprehensive coverage of the medical process with its large model [5]

Meeting Overview - The shareholder meeting of Wuxi Xiangsheng Medical Technology Co., Ltd. was held on May 16, 2025, at the company's conference room [1] - A total of 40 ordinary shareholders attended the meeting, representing 82,221,541 voting rights, which accounts for 73.3305% of the total voting rights of the company [1] Voting Results - All non-cumulative voting proposals were approved with a significant majority, including: - 99.9857% of ordinary shareholders voted in favor of the proposals, with only 0.0143% against [2] - The voting results for the financial budget report for 2025 also showed a similar trend, with 99.9857% approval [2] - The meeting's voting procedures complied with the Company Law and the company's articles of association, confirming the legality and validity of the meeting [3] Legal Compliance - The lawyers present at the meeting confirmed that the convening and voting procedures adhered to relevant laws and regulations, ensuring the legitimacy of the meeting and its outcomes [3]

本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予以了 核查、验证。在进行核查验证过程中, 公司已向本所保证, 公司提供予本所之文件中的所有 签署、盖章及印章都是真实的, 所有作为正本提交给本所的文件都是真实、准确、完整和有 效的, 且文件材料为副本或复印件的, 其与原件一致和相符。 在本法律意见书中, 本所仅对本次股东大会召集和召开的程序、出席本次股东大会人员 资格和召集人资格及表决程序、表决结果是否符合法律法规和公司章程的规定发表意见, 并 不对本次股东大会所审议的议案内容以及该等议案所表述的事实或数据的真实性和准确性 发表意见。 本所及本所律师依据法律法规及本法律意见出具日以前已经发生或者存在的事实, 严 格履行了法定职责, 遵循了勤勉尽责和诚实信用原则, 进行了充分的核查验证, 保证本法律 意见所认定的事实真实、准确、完整, 所发表的结论性意见合法、准确, 不存在虚假记载、 1981010/WS/kw/cm/D19 上海市通力律师事务所 关于无锡祥生医疗科技股份有限公司 2024 年年度股东大会的法律意见书 致: 无锡祥生医疗科技股份有限公司 上海市通力律师事务所(以下简称"本所" ...

证券代码：688358 证券简称：祥生医疗 公告编号：2025-016 无锡祥生医疗科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 16 日 （二） 股东大会召开的地点：无锡市新吴区新辉环路 9 号 公司一楼会议室 3、 董事会秘书、财务负责人周峰先生出席了本次会议；见证律师列席本次会议。 二、 议案审议情况 （一） 非累积投票议案 1、 议案名称：《关于 2024 年年度报告正文及其摘要的议案》 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 40 | | --- | --- | | 普通股股东人数 | 40 | | 2、出席会议的股东所持有的表决权数量 | 82,221,541 | | 普通股股东所持有表决权数量 | 82,221,541 | | 3、出席会议的股 ...